Akebia Therapeutics, Inc

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Arkuda is comprised of passionate and experienced team members who are dedicated to improving the lives of people affected by neurodegenerative disease. Armed with deep expertise in biology and the ab

Alkermes is a worldwide pharmaceutical company that develops controlled, sustained-release injectable drugs using with its trademark ProLease and Medisorb technologies. Located in Massachusetts, the company also develops inhaled formulations from its proprietary pulmonary technology. Alkermes has partnered with Johnson & Johnson to develop Riserpdal Consta, an antipsychotic drug used in the treatment of schizophrenia. Risperdal Consta is approved for sale in more than 50 countries that include the United States, United Kingdom and Germany. In addition to a host of partnered products, the ocmpany is also active in the development of several promising proprietary products, such as Vivitrex, a long-acting injectable form of naltrexone for alcohol dependence. Alkermes is headquartered in Cambridge, Mass.